A recent study showed that a CAR design using the receptor-binding domain of APRIL as the tumor antigen-targeting domain (APRIL-based chimeric antigen receptors; ACAR), which recognizes both BCMA and TACI on MM cells, could potentially improve clinical outcomes [84]. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.